Drug intelligence / Profile preview

MF4637

Development stage: Unknown
Lead developer: BASF
Modality: Small Molecules
Administration: Oral

Overview

MF4637 is a high-concentrate omega-3 fatty acid medical food preparation containing eicosapentaenoic acid (EPA) ethyl ester (460 mg per 1 g capsule) and docosahexaenoic acid (DHA) ethyl ester (380 mg per 1 g capsule), administered as three capsules daily to provide 1.38 g EPA and 1.14 g DHA. Developed to address omega-3 nutritional deficiency in patients with non-alcoholic fatty liver disease (NAFLD), it significantly increases the red blood cell omega-3 index (RBC EPA + DHA) and reduces the RBC omega-6:omega-3 ratio compared to placebo in a 24-week randomized controlled trial. Exploratory outcomes suggested potential benefits on hepatic fat content measured by MRI-PDFF, alongside reductions in triglycerides, with a favorable safety profile.[1][3][6]

Beyond the preview

Go deeper on MF4637.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MF4637.

Explore the full profile